Live feed
Filing
SCHEDULE 13D/A
SCHEDULE 13D/A0001999371-25-007493·Monograph Capital Holdings Advisors, LLC
Schedule 13D ownership disclosure
UROGEN PHARMA LTD
Ordinary Shares, par value NIS 0.01 per share · CUSIP: M96088105
Event date: 2025-06-05
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Monograph Capital Partners I, L.P.Reported CIK 0001864082
Shares: 838,615.00 · Class: 1.8%
- Monograph Capital Partners I GenPar, LP
Shares: 838,615.00 · Class: 1.8%
- Monograph Capital Holdings Advisors, LLCReported CIK 0001988760
Shares: 838,615.00 · Class: 1.8%
- Fred CohenReported CIK 0001339358
Shares: 838,615.00 · Class: 1.9%
- Charles Conn
Shares: 838,615.00 · Class: 1.8%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001999371-25-007493
- Form type
- SCHEDULE 13D/A
- Filer
- Monograph Capital Holdings Advisors, LLC
- CIK
- CIK 1988760
- Filed
- Jun 09, 2025
- Reporting period
- Jun 05, 2025
- Description
- Schedule 13D beneficial ownership